| Date | Title | Description |
| 30.05.2025 | NEW THERAPY FOR CHILDREN WITH GROWTH HORMONE DEFICIENCY APPROVED IN AUSTRALIA | SKYTROFA® (lonapegsomatropin) is now registered by the Therapeutic Goods Administration (TGA) for the treatment of paediatric growth hormone deficiency.[1]
SINGAPORE, May 30, 2025 /PRNewswire/ -- Independent biopharmaceutical company Specia... |
| 12.05.2025 | New 4-Year Data Shows Sustained Response to TransCon® PTH (Palopegteriparatide) Therapy in Adults with Hypoparathyroidism | COPENHAGEN, Denmark, May 12, 2025 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced new data from Week 214 of its Phase 2 PaTH Forward Trial showing that long-term treatment with TransCon PTH (palopegteriparatide) conti... |
| 24.04.2025 | Ascendis Pharma to Report First Quarter 2025 Financial Results and Provide Business Update on May 1, 2025 | COPENHAGEN, Denmark, April 24, 2025 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced it will report first quarter 2025 financial results and provide a business update on Thursday, May 1, 2025, after the close of the U.... |
| 31.03.2025 | Ascendis Submits U.S. NDA for TransCon CNP (Navepegritide) for the Treatment of Children with Achondroplasia | — Data demonstrated multiple clinical benefits beyond linear growth
— NDA supported by data from three randomized, double-blind, placebo-controlled clinical trials in children with achondroplasia, with up to three years of open-label extens... |
| 21.02.2025 | FIRST AND ONLY TREATMENT FOR CHRONIC HYPOPARATHYROIDISM APPROVED IN AUSTRALIA | YORVIPATH® (palopegteriparatide) is now registered by the Therapeutic Goods Administration (TGA) for the treatment of chronic hypoparathyroidism in adults1
First-in-class novel PTH replacement therapy
Australia becomes the first country to ... |
| 12.02.2025 | Ascendis Pharma Reports Fourth Quarter and Full Year 2024 Financial Results | – Strong early U.S. YORVIPATH® launch with 908 prescriptions as of Feb. 7, 2025; YORVIPATH full year 2024 revenue of €28.7 million
– Following pre-NDA meeting with FDA, on track to submit TransCon™ CNP NDA for achondroplasia in children in ... |
| 12.02.2025 | Ascendis Pharma A/S Announces Share Repurchase Program & Net Settlement of Certain RSUs | – Expected use of approximately $25 million in first quarter of 2025 intended to preserve approximately 200,000 ADSs held as treasury shares
COPENHAGEN, Denmark, Feb. 12, 2025 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today ann... |
| 05.02.2025 | Ascendis Pharma to Report Full Year 2024 Financial Results and Provide Business Update on February 12, 2025 | COPENHAGEN, Denmark, Feb. 05, 2025 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced it will report full year 2024 financial results and provide a business update on Wednesday, February 12, 2025, after the close of the ... |
| 05.02.2025 | Ascendis Pharma to Report Full Year 2024 Financial Results and Provide Business Update on February 12, 2025 | COPENHAGEN, Denmark, Feb. 05, 2025 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced it will report full year 2024 financial results and provide a business update on Wednesday, February 12, 2025, after the close of the ... |
| 12.01.2025 | Ascendis Pharma Provides Business and Strategic Roadmap Update at 43rd Annual J.P. Morgan Healthcare Conference | - Ascendis positioned to drive rapid revenue growth
COPENHAGEN, Denmark, Jan. 12, 2025 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today provided a business and strategic roadmap update, including planned 2025 key corporate miles... |
| 06.01.2025 | Ascendis Pharma to Participate in the 43rd Annual J.P. Morgan Healthcare Conference | COPENHAGEN, Denmark, Jan. 06, 2025 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that company executives will participate in the 43rd Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2025, at 11:15 a.... |
| 19.12.2024 | YORVIPATH® (Palopegteriparatide) Now Commercially Available in the United States for the Treatment of Hypoparathyroidism in Adults | COPENHAGEN, Denmark, Dec. 19, 2024 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that YORVIPATH® (palopegteriparatide; developed as TransCon PTH) is now commercially available by prescription in the United States. Y... |
| 16.12.2024 | New InsiGHTS Trial of TransCon™ hGH (Lonapegsomatropin) in Turner Syndrome Achieved Primary Objective at Week 26 | - Results for all three TransCon hGH starting dose cohorts, in first clinical trial of an indication outside of growth hormone deficiency, showed a safety and tolerability profile comparable to daily somatropin
- Annualized height velocity ... |
| 12.12.2024 | FDA Accepts Ascendis Pharma’s Supplemental Biologics License Application for TransCon™ hGH for the Treatment of Adults with Growth Hormone Deficiency | COPENHAGEN, Denmark, Dec. 12, 2024 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that the U.S. Food & Drug Administration (FDA) has accepted for review its supplemental Biologics License Application (sBLA) in ad... |
| 04.11.2024 | Ascendis Pharma and Novo Nordisk Sign Collaboration for Development and Commercialization of TransCon Technology-based Products in Metabolic and Cardiovascular Diseases | - Collaboration leverages Ascendis’ proprietary TransCon™ technologies and Novo Nordisk’s expertise in cardiometabolic diseases
- Once-monthly GLP-1 receptor agonist will be the collaboration’s lead product candidate
COPENHAGEN, Denmark, No... |
| 30.09.2024 | Ascendis Pharma Announces Submission of Supplemental Biologics License Application to FDA for TransCon™ hGH for the Treatment of Adults with Growth Hormone Deficiency | COPENHAGEN, Denmark, Sept. 30, 2024 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced it has submitted a supplemental Biologics License Application (sBLA) to the U.S. Food & Drug Administration (FDA) for TransCon hG... |
| 30.09.2024 | New 3-Year Skeletal Dynamics Data for Adults with Hypoparathyroidism Treated with TransCon™ PTH (Palopegteriparatide) Presented at ASBMR 2024 | COPENHAGEN, Denmark, Sept. 30, 2024 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) shared 3-year results from the Company’s ongoing Phase 2 PaTH Forward Trial of 57 adults with hypoparathyroidism showing that long-term treatment wit... |
| 19.09.2024 | Ascendis Pharma A/S Announces Pricing of Public Offering of ADSs | COPENHAGEN, Denmark, Sept. 20, 2024 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced the pricing of its underwritten public offering of 2,000,000 American Depositary Shares (“ADSs”), each of which represents one ordina... |
| 18.09.2024 | Ascendis Pharma A/S Announces Proposed Public Offering of ADSs | COPENHAGEN, Denmark, Sept. 18, 2024 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that it has commenced an underwritten public offering of $300,000,000 of American Depositary Shares (“ADSs”), each of which represent... |
| 13.09.2024 | Ascendis to Present First Results from Platinum-Resistant Ovarian Cancer (PROC) Cohort of the Phase 1/2 IL-Believe Trial at ESMO 2024 | Anti-tumor clinical responses were observed in 29% (4/14) of efficacy-evaluable patients with PROC treated with TransCon IL-2 β/γ in combination with chemotherapy Initial data suggest clinical activity in heavily pre-treated PROC patients a... |
| 13.09.2024 | Ascendis to Present First Results from Platinum-Resistant Ovarian Cancer (PROC) Cohort of the Phase 1/2 IL-Believe Trial at ESMO 2024 | Anti-tumor clinical responses were observed in 29% (4/14) of efficacy-evaluable patients with PROC treated with TransCon IL-2 β/γ in combination with chemotherapy Initial data suggest clinical activity in heavily pre-treated PROC patients a... |
| 11.09.2024 | Ascendis Pharma Receives Orphan Drug Exclusivity in the U.S. for YORVIPATH® (Palopegteriparatide) for the Treatment of Hypoparathyroidism in Adults | – U.S. FDA Orphan Drug exclusivity provides seven years of market exclusivity for YORVIPATH in the United States for the treatment of hypoparathyroidism in adults
COPENHAGEN, Denmark, Sept. 11, 2024 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (... |
| 04.09.2024 | Ascendis Pharma and Royalty Pharma: A $150 Million Leap into Innovation | In a bold move that echoes through the biopharmaceutical landscape, Ascendis Pharma A/S and Royalty Pharma plc have forged a significant partnership. The duo has entered into a $150 million capped synthetic royalty funding agreement. This d... |
| 03.09.2024 | Ascendis Pharma Reports Second Quarter 2024 Financial Results | YORVIPATH approved by U.S. Food & Drug Administration (FDA) as the first and only treatment of hypoparathyroidism in adultsTransCon CNP (navepegritide) pivotal ApproaCH Trial topline results expected in the coming weeksSKYTROFA Q2 reven... |
| 03.09.2024 | Ascendis Pharma and Royalty Pharma Enter into $150 Million Royalty Funding Agreement | Proceeds to support continued development and commercialization of Endocrine Rare Disease products, including the YORVIPATH® U.S. commercial launch, and general corporate purposes
COPENHAGEN, Denmark and NEW YORK, Sept. 03, 2024 (GLOBE NEWS... |
| 03.09.2024 | Royalty Pharma and Ascendis Pharma Enter Into $150 Million Royalty Funding Agreement | Proceeds to support continued development and commercialization of Endocrine Rare Disease products, including the Yorvipath U.S. commercial launch, and general corporate purposes
NEW YORK and COPENHAGEN, Denmark, Sept. 03, 2024 (GLOBE NEWSW... |
| 03.09.2024 | Ascendis Pharma Reports Second Quarter 2024 Financial Results | YORVIPATH approved by U.S. Food & Drug Administration (FDA) as the first and only treatment of hypoparathyroidism in adults TransCon CNP (navepegritide) pivotal ApproaCH Trial topline results expected in the coming weeks SKYTROFA Q2 rev... |
| 03.09.2024 | Ascendis Pharma and Royalty Pharma Enter into $150 Million Royalty Funding Agreement | COPENHAGEN, Denmark and NEW YORK, Sept. 03, 2024 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) and Royalty Pharma plc (Nasdaq: RPRX) today announced that Ascendis Pharma Bone Diseases A/S, a wholly-owned subsidiary of Ascendis Phar... |
| 03.09.2024 | Royalty Pharma and Ascendis Pharma Enter Into $150 Million Royalty Funding Agreement | NEW YORK and COPENHAGEN, Denmark, Sept. 03, 2024 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) and Ascendis Pharma A/S (Nasdaq: ASND) today announced that Royalty Pharma and Ascendis Pharma Bone Diseases A/S, a wholly-owned subsidia... |
| 24.06.2024 | Data from Phase 2 ACcomplisH Trial of TransCon CNP in Children with Achondroplasia Presented at ICCHBH 2024 | • Data demonstrate significant improvements in well-being and physical functioning compared to placebo in patients treated for 1 year with TransCon CNP at the pivotal 100μg/kg/week dose
• Improvements could not be explained by changes in li... |
| 24.06.2024 | Data from Phase 2 ACcomplisH Trial of TransCon CNP in Children with Achondroplasia Presented at ICCHBH 2024 | • Data demonstrate significant improvements in well-being and physical functioning compared to placebo in patients treated for 1 year with TransCon CNP at the pivotal 100μg/kg/week dose
• Improvements could not be explained by changes in li... |
| 04.06.2024 | Ascendis Pharma to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference | COPENHAGEN, Denmark, June 04, 2024 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that company executives will participate in a fireside chat at the Goldman Sachs 45th Annual Global Healthcare Conference on Tuesday, ... |
| 03.06.2024 | Ascendis Pharma Presents New Data and Updated Results from Phase 1/2 IL-Believe Trial at ASCO 2024 | - 40% of efficacy-evaluable patients (2 out of 5) in the initial cohort of patients with anti-PD-1 refractory melanoma treated with TransCon IL-2 β/γ in combination with TransCon TLR7/8 Agonist exhibited confirmed clinical responses with no... |
| 30.05.2024 | Ascendis to Spotlight Latest Updates for TransCon™ Rare Endocrinology Disease Portfolio at ENDO 2024 | COPENHAGEN, Denmark, May 30, 2024 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that it will host informational booths, events, and presentations showcasing use of its innovative TransCon technology in the areas of ... |
| 14.05.2024 | Ascendis Pharma Announces Extension of U.S. Food and Drug Administration Review Period for TransCon™ PTH for Adults with Hypoparathyroidism | - Prescription Drug User Fee Act (PDUFA) goal date extended by three months for further review of submission to August 14, 2024
COPENHAGEN, Denmark, May 14, 2024 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that th... |
| 14.03.2024 | AstraZeneca Acquisition Brings Drug to Fill a Rare Disease Gap Left by Takeda | AstraZeneca is bolstering its rare disease pipeline with a deal to buy Amolyt Pharma, a biotech company in late-stage development with a therapy designed to treat a rare hormone deficiency whose only FDA-approved treatment will soon cease p... |
| 03.03.2024 | 'There's an enormous catch-up trade': These 5 small-cap stocks are destined to soar, according to a stock researcher behind a top-11% fund in the last 5 years | Markets 'There's an enormous catch-up trade': These 5 small-cap stocks are destined to soar, according to a stock researcher behind a top-11% fund in the last 5 years
James Faris
2024-03-03T10:07:01Z
Share icon An curved arrow pointing righ... |
| 31.01.2024 | Ascendis Pharma Launches 2nd TransCon™ Product: YORVIPATH® Now Available in Germany and Austria for Adults with Chronic Hypoparathyroidism | COPENHAGEN, Denmark, Jan. 31, 2024 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that YORVIPATH® (palopegteriparatide, developed as TransCon PTH), a parathyroid hormone (PTH) replacement therapy indicated for the tr... |
| 31.01.2024 | Ascendis Pharma to Report Full Year 2023 Financial Results and Provide Business Update on February 7, 2024 | COPENHAGEN, Denmark, Jan. 31, 2024 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced it will report full year 2023 financial results and provide a business update on Wednesday, February 7, 2024, after the close of the U... |
| 16.11.2023 | Once-Weekly TransCon™ CNP Achieved Primary Efficacy Objective in ACcomplisH China Phase 2 Trial | SHANGHAI, Nov. 16, 2023 /PRNewswire/ -- VISEN Pharmaceuticals (VISEN), an innovative biopharmaceutical company focused on endocrine diseases, is pleased to announce the topline results from the ACcomplisH China Phase 2 Trial in children wit... |
| 05.06.2023 | Ascendis Pharma Opens Compassionate Use Program for TransCon™ PTH (palopegteriparatide) in Germany | /EIN News/ -- – Compassionate use enables treating physicians in Germany to request access to investigational TransCon PTH (palopegteriparatide) for eligible adult patients with hypoparathyroidism
COPENHAGEN, Denmark, June 05, 2023 (GLOBE N... |
| 31.05.2023 | Ascendis Pharma Oncology Program Update Highlights Latest Clinical Data for Product Candidates | /EIN News/ -- – TransCon IL-2 β/γ in Phase 1 clinical trial showed monotherapy clinical activity in heavily pre-treated cancer patients with clear dose dependent response on cytotoxic immune cells
– TransCon IL-2 β/γ administered every 3 we... |
| 25.05.2023 | Ascendis Pharma to Host Oncology Program Update on May 31 | /EIN News/ -- COPENHAGEN, Denmark, May 25, 2023 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced the company will host an Oncology program update for the investment community on Wednesday, May 31, 2023 in New York from... |
| 13.05.2023 | Ascendis Pharma Showcases Commitment to Rare Endocrine Diseases at the 25th European Congress of Endocrinology 2023 | /EIN News/ -- COPENHAGEN, Denmark, May 13, 2023 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced the company will present clinical and research outcomes in hypoparathyroidism and growth hormone deficiency, and host inf... |
| 03.05.2023 | Ascendis Pharma to Participate in the BofA Securities 2023 Health Care Conference | /EIN News/ -- COPENHAGEN, Denmark, May 03, 2023 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that Jan Mikkelsen, President & Chief Executive Officer, and Scott Smith, Executive Vice President & Chief Financ... |
| 07.02.2023 | Ascendis Pharma Announces Full Year 2022 Financial Results and Business Update Conference Call on February 16 | /EIN News/ -- COPENHAGEN, Denmark, Feb. 07, 2023 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that the company will hold a conference call and live webcast on Thursday, February 16, 2023, at 4:30 p.m. Eastern Time ... |
| 04.01.2023 | Online Enrollment Now Open for Physicians Requesting Expanded Access to Ascendis Pharma’s TransCon™ PTH for Eligible U.S. Adult Patients with Hypoparathyroidism | /EIN News/ -- - The Expanded Access Program (EAP) allows physicians to request access to TransCon PTH, the company’s investigational parathyroid hormone replacement therapy, for eligible patients in the United States
- TransCon PTH is under... |
| 22.11.2022 | Ascendis Pharma to Participate in the 5th Annual Evercore ISI HealthCONx Conference | /EIN News/ -- COPENHAGEN, Denmark, Nov. 22, 2022 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) announced today that the company is scheduled to participate in the 5th Annual Evercore ISI HealthCONx Conference. Company executives wi... |
| 11.11.2022 | Dose Escalation Data from transcendIT-101, Ascendis Pharma’s Phase 1/2 Trial of TransCon™ TLR7/8 Agonist in Patients with Advanced Solid Tumors, Presented at SITC 2022 | /EIN News/ -- - Early signs of clinical activity were observed in patients receiving TransCon TLR7/8 Agonist as monotherapy or in combination with pembrolizumab; abscopal effect observed with monotherapy
- With a single injection, TransCon ... |
| 31.10.2022 | FDA Accepts for Priority Review Ascendis Pharma’s NDA for TransCon™ PTH in Adult Patients with Hypoparathyroidism | - PDUFA target action date is April 30, 2023
- MAA submission to EMA on track for this quarter
COPENHAGEN, Denmark, Oct. 31, 2022 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that the U.S. Food & Drug Administr... |
| 26.10.2022 | Ascendis Pharma A/S Announces Third Quarter 2022 Financial Results and Business Update Conference Call on November 2 | /EIN News/ -- COPENHAGEN, Denmark, Oct. 26, 2022 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) announced today that the company will hold a conference call and live webcast on Wednesday, November 2, 2022, at 4:30 p.m. Eastern Time ... |
| 26.10.2022 | Ascendis Pharma A/S Announces Third Quarter 2022 Financial Results and Business Update Conference Call on November 2 | COPENHAGEN, Denmark, Oct. 26, 2022 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) announced today that the company will hold a conference call and live webcast on Wednesday, November 2, 2022, at 4:30 p.m. Eastern Time (ET) to review... |
| 03.10.2022 | Ascendis Pharma Announces Recommended Phase 2 Dose and Cohort Expansion for transcendIT-101, a Phase 1/2 Clinical Trial of TransCon™ TLR7/8 Agonist in Solid Tumors | - TransCon TLR7/8 Agonist continued to be well-tolerated and demonstrated early signs of clinical activity as monotherapy or in combination with pembrolizumab
- Abstract for dose-escalation topline data accepted for an oral presentation at ... |
| 12.09.2022 | New Long-Term Data in Adult Patients with Hypoparathyroidism Treated with Ascendis Pharma’s TransCon™ PTH through Week 110 in the PaTH Forward Trial Presented at ASBMR 2022 | - Durability of response to TransCon PTH therapy through Week 110 demonstrated by continued normalization of serum calcium and 93% achieving independence from conventional therapy
- Participants with more years of disease duration had highe... |
| 01.09.2022 | Ascendis Pharma A/S Announces Upcoming Investor Presentations in September | COPENHAGEN, Denmark, Sept. 01, 2022 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) announced today that the company is scheduled to participate in three upcoming investor conferences in September.
Details:
Event Citi's 17th Annual B... |
| 31.08.2022 | Ascendis Pharma Submits TransCon™ PTH New Drug Application to the U.S. FDA for Adult Patients with Hypoparathyroidism | • TransCon PTH could, if approved, become the first hormone replacement therapy to address the underlying cause of hypoparathyroidism, an area of major unmet medical need for the estimated 70,000-90,000 adults living with chronic disease in... |
| 10.08.2022 | Ascendis Pharma A/S Reports Second Quarter 2022 Financial Results | — U.S. regulatory submission for TransCon PTH, designed to be the first parathyroid hormone replacement therapy, on track for Q3 2022; EU submission planned for Q4 2022
— SKYTROFA revenue continued to double quarter-to-quarter, reaching €4.... |
| 04.08.2022 | Ascendis Pharma A/S Announces Second Quarter 2022 Financial Results and Business Update Conference Call on August 10 | COPENHAGEN, Denmark, Aug. 04, 2022 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) announced today that the company will hold a conference call and live webcast on Wednesday, August 10, 2022, at 4:30 p.m. Eastern Time (ET) to review ... |
| 07.06.2022 | Ascendis Pharma A/S Announces Two Oral Presentations Highlighting the Potential for TransCon™ PTH to be a Replacement Therapy for Adult Hypoparathyroidism at ENDO 2022 | – Late-breaker oral presentation of TransCon PTH Phase 3 PaTHway Trial data in adult hypoparathyroidism on Tuesday, June 14
– Oral presentation of TransCon PTH Phase 2 PaTH Forward Trial Open-Label Extension Data in adult hypoparathyroidism... |
| 23.05.2022 | Ascendis Pharma A/S Announces New Commercial Endocrinology Leadership Appointments | - Joe Kelly has been appointed to the newly created role of Head of U.S. Commercial, Endocrinology
- Scott A. Holmes has been appointed to the newly created role of Head of Global Commercial Strategy, Endocrinology
- Jesper Høiland, Global ... |
| 23.05.2022 | Positive Results from VISEN’s Phase 3 Trial of Once-Weekly TransCon hGH in China Consistent with Ascendis Pharma’s Phase 3 Height Trial | - VISEN’s Phase 3 Trial achieved primary endpoint; pediatric growth hormone deficiency (GHD) patients treated with TransCon™ hGH demonstrated greater annualized height velocity at 52-weeks (p=0.0010) compared to patients treated with daily ... |
| 11.05.2022 | Ascendis Pharma A/S Reports First Quarter 2022 Financial Results | Phase 3 PaTHway Trial top-line results demonstrated potential of TransCon™ PTH to become the first parathyroid replacement therapy for adults with hypoparathyroidism
TransCon PTH U.S. FDA regulatory submission on track for Q3 and EU MAA for... |
| 09.05.2022 | Ascendis Pharma A/S to Participate in the BofA Securities 2022 Healthcare Conference | COPENHAGEN, Denmark, May 09, 2022 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) announced today that the company is scheduled to attend the BofA Securities 2022 Healthcare Conference. Company executives will participate in a firesi... |
| 04.05.2022 | Ascendis Pharma A/S Announces First Quarter 2022 Financial Results and Business Update Conference Call on May 11 | COPENHAGEN, Denmark, May 04, 2022 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) announced today that the company will hold a conference call and live webcast on Wednesday, May 11, 2022 at 4:30 p.m. Eastern Time (ET) to review its f... |
| 01.05.2022 | Ascendis Pharma A/S to Present New Endocrinology Results at Four Medical Meetings in May | New data highlights include:
- Phase 3 open-label extension study data for growth hormone-deficient children treated for 2.5 years with TransConTM hGH
- Initial findings from research on comorbidities associated with adult growth hormone de... |
| 13.03.2022 | Ascendis Pharma A/S Announces Phase 3 PaTHway Trial of TransCon™ PTH in Adults with Hypoparathyroidism Met Primary and All Key Secondary Endpoints | – For the primary composite endpoint, TransCon PTH demonstrated a response rate of 78.7% compared to 4.8% for control (p-value |
| 02.03.2022 | Ascendis Pharma A/S Reports Full Year 2021 Financial Results and Provides a Business Update | - Top-line results from PaTHway, a Phase 3 randomized study evaluating the safety, tolerability, and efficacy of TransCon™ PTH in adult hypoparathyroidism (HP) patients on track for this quarter
- Demand for SKYTROFA® (lonapegsomatropin-tcg... |
| 25.02.2022 | Ascendis Pharma A/S Announces Full Year 2021 Financial Results and Business Update Conference Call on March 2 | COPENHAGEN, Denmark, Feb. 25, 2022 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that the Company will hold a conference call and live webcast on Wednesday, March 2, 2022 at 4:30 p.m. Eastern Time (ET) to review its... |
| 11.02.2022 | Ascendis Pharma A/S to Participate in the 11th Annual SVB Leerink Global Healthcare Conference | COPENHAGEN, Denmark, Feb. 10, 2022 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that the Company is scheduled to participate in the 11th Annual SVB Leerink Global Healthcare Conference. Company executives will part... |
| 10.02.2022 | Ascendis Pharma A/S to Participate in the 11th Annual SVB Leerink Global Healthcare Conference | COPENHAGEN, Denmark, Feb. 10, 2022 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that the Company is scheduled to participate in the 11th Annual SVB Leerink Global Healthcare Conference. Company executives will part... |
| 13.01.2022 | Ascendis Pharma A/S Receives European Approval for TransCon™ hGH for Pediatric Growth Hormone Deficiency | COPENHAGEN, Denmark, Jan. 13, 2022 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that the European Commission (EC) has granted marketing authorization for Lonapegsomatropin Ascendis Pharma (developed under the name ... |
| 10.01.2022 | Ascendis Pharma A/S Provides Update on Vision 3x3 Strategic Roadmap at 40th Annual J.P. Morgan Healthcare Conference | COPENHAGEN, Denmark, Jan. 10, 2022 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that the Company will today provide an update on its Vision 3x3 and planned 2022 key milestones at the 40th Annual J.P. Morgan Healthc... |
| 04.01.2022 | Ascendis Pharma A/S to Participate in 40th Annual J.P. Morgan Healthcare Conference | COPENHAGEN, Denmark, Jan. 04, 2022 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that the Company is scheduled to participate in the upcoming 40th Annual J.P. Morgan Healthcare Conference. Company executives will pr... |
| 04.01.2022 | Ascendis Pharma A/S to Participate in 40th Annual J.P. Morgan Healthcare Conference | COPENHAGEN, Denmark, Jan. 04, 2022 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that the Company is scheduled to participate in the upcoming 40th Annual J.P. Morgan Healthcare Conference. Company executives will pr... |
| 14.12.2021 | Ascendis Pharma A/S Virtual R&D Program Update Highlights Continued Development Across R&D Pipeline | –– TransCon™ PTH Phase 3 topline results expected in Q1 2022 and, if positive, planned NDA submission in Q3 2022 followed by expected MAA submission in Q4 2022
–– Enrollment completed in Phase 2 ACcomplisH Trial of TransCon CNP; blinded dat... |
| 07.12.2021 | Ascendis Pharma A/S to Host Virtual R&D Program Update on December 14 | COPENHAGEN, Denmark, Dec. 07, 2021 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that the Company will host a virtual R&D Program Update for the investment community on Tuesday, December 14, 2021.
The event will... |
| 19.11.2021 | Ascendis Pharma A/S Announces Top-Line Results from Week 84 of Its Phase 2 PaTH Forward Trial Demonstrating that TransCon™ PTH Provided Durable Benefit and Was Well-Tolerated in Adults with Hypoparath... | –– 58 of the original 59 subjects continue in the open-label extension portion of the Phase 2 trial.
–– Phase 3 data for TransCon PTH expected in Q1 2022.
COPENHAGEN, Denmark, Nov. 18, 2021 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: A... |
| 18.11.2021 | Ascendis Pharma A/S Announces Top-Line Results from Week 84 of Its Phase 2 PaTH Forward Trial Demonstrating that TransCon™ PTH Provided Durable Benefit and Was Well-Tolerated in Adults with Hypoparath... | –– 58 of the original 59 subjects continue in the open-label extension portion of the Phase 2 trial.
–– Phase 3 data for TransCon PTH expected in Q1 2022.
COPENHAGEN, Denmark, Nov. 18, 2021 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: A... |
| 17.11.2021 | Ascendis Pharma A/S to Participate in the Evercore ISI 4th Annual HealthCONx Conference | COPENHAGEN, Denmark, Nov. 17, 2021 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that the Company is scheduled to participate in the Evercore ISI 4th Annual HealthCONx Conference. Company executives will participate... |
| 15.11.2021 | Ascendis Pharma A/S - Share Repurchase Program Update | COPENHAGEN, Denmark, Nov. 15, 2021 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today provided an update on the Company’s previously announced $25 million American Depositary Shares (ADS) Share Repurchase Program. Each ADS represe... |
| 12.11.2021 | Ascendis Pharma A/S Receives Positive CHMP Opinion for TransCon™ hGH for Patients with Pediatric Growth Hormone Deficiency | – TransCon hGH is a once-weekly prodrug of somatropin designed to reduce the treatment burden for patients with growth hormone deficiency.
– Final European Commission decision on TransCon hGH MAA for pediatric growth hormone deficiency expe... |
| 12.11.2021 | Ascendis Pharma A/S Receives Positive CHMP Opinion for TransCon™ hGH for Patients with Pediatric Growth Hormone Deficiency | – TransCon hGH is a once-weekly prodrug of somatropin designed to reduce the treatment burden for patients with growth hormone deficiency.
– Final European Commission decision on TransCon hGH MAA for pediatric growth hormone deficiency expe... |
| 11.11.2021 | Ascendis Pharma A/S Reports Third Quarter 2021 Financial Results | – SKYTROFA® (lonapegsomatropin-tcgd) approved by the FDA in the U.S. as a once-weekly treatment for pediatric growth hormone deficiency (GHD); commercially launched in October 2021.
– Completed enrollment in Phase 3 PaTHway Trial of TransCo... |
| 11.11.2021 | Ascendis Pharma A/S Reports Third Quarter 2021 Financial Results - Form 6-K | Ascendis Pharma A/S Reports Third Quarter 2021 Financial Results
- SKYTROFA® (lonapegsomatropin-tcgd) approved by the FDA in the U.S. as a once-weekly treatment for pediatric growth hormone deficiency (GHD); commercially launched in October... |
| 10.11.2021 | Ascendis Pharma A/S Reports Third Quarter 2021 Financial Results | – SKYTROFA® (lonapegsomatropin-tcgd) approved by the FDA in the U.S. as a once-weekly treatment for pediatric growth hormone deficiency (GHD); commercially launched in October 2021.
– Completed enrollment in Phase 3 PaTHway Trial of TransCo... |
| 09.11.2021 | Ascendis Pharma A/S Presents New Non-Clinical Data for TransCon™ TLR7/8 Agonist Oncology Program at SITC 2021 | - In non-clinical models, a single dose of TransCon™ TLR7/8 Agonist activated critical innate and adaptive immune mechanisms, providing sustained modulation of tumor microenvironments with low systemic exposure.
- Company on track to announ... |
| 08.11.2021 | Ascendis Pharma A/S - Share Repurchase Program Update | COPENHAGEN, Denmark, Nov. 08, 2021 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today provided an update on the Company’s previously announced $25 million American Depositary Shares (ADS) Share Repurchase Program. Each ADS represe... |
| 03.11.2021 | Ascendis Pharma A/S Announces Third Quarter 2021 Financial Results and Business Update Conference Call on November 10 | COPENHAGEN, Denmark, Nov. 03, 2021 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND), today announced that the Company will hold a conference call and live webcast on Wednesday, November 10, 2021 at 4:30 p.m. Eastern Time (ET) to revie... |
| 15.10.2021 | Ascendis Pharma A/S Announces U.S. Commercial Launch of SKYTROFA® (Lonapegsomatropin-tcgd), the First and Only FDA Approved Once-Weekly Treatment for Pediatric Growth Hormone Deficiency | COPENHAGEN, Denmark, Oct. 15, 2021 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND), today announced the U.S. commercial launch of SKYTROFA (lonapegsomatropin-tcgd), its once-weekly treatment for the treatment of pediatric patients on... |
| 30.09.2021 | Ascendis Pharma A/S : A/S Announces Presentations for TransCon™ PTH and TransCon™ CNP at the American Society for Bone & Mineral Research 2021 Annual Meeting | – Late-breaking oral presentation will feature a comprehensive review of 58-week results from the company’s Phase 2 PaTH Forward Trial –
COPENHAGEN, Denmark, Sept. 30, 2021 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND), a biopharma... |
| 29.09.2021 | Ascendis Pharma A/S announces an Equity Buyback for 300,000 shares, for $25 million. | Ascendis Pharma A/S (NasdaqGS:ASND) announces a share repurchase program. Under the program, the company will repurchase up to 300,000 American Depositary Shares, for $25 million. The purpose of the program is to acquire ADS needed in conne... |
| 22.09.2021 | Ascendis Pharma A/S Announces Mean Bone Mineral Density (BMD) Data from Phase 2 PaTH Forward Trial Demonstrating Continued Normalization and Stabilization of BMD Z-scores Between 26 and 58 Weeks | – Data from subjects with available dual energy x-ray absorptiometry (DXA) scans demonstrated stabilization of BMD, in alignment with observed bone turnover markers previously reported –
COPENHAGEN, Denmark, Sept. 22, 2021 (GLOBE NEWSWIRE) ... |
| 08.09.2021 | Ascendis Pharma A/S Submits Investigational New Drug Application to Initiate TransCon™ IL-2 β/γ Clinical Program | – TransCon IL-2 β/γ is an investigational long-acting prodrug designed to improve cancer immunotherapy through the sustained systemic release of an IL-2 variant with potential for prolonged activation of IL-2Rβ/γ with low Cmax –
COPENHAGEN,... |
| 08.09.2021 | Ascendis Pharma A/S Announces Upcoming Investor Presentations | COPENHAGEN, Denmark, Sept. 07, 2021 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon™ technologies to potentially create new treatments that make a meaningful differen... |
| 02.09.2021 | Ascendis Pharma A/S Announces Pricing of Public Offering of ADSs | COPENHAGEN, Denmark, Sept. 01, 2021 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon™ technologies to potentially create new treatments that make a meaningful differen... |
| 31.08.2021 | Ascendis Pharma A/S Announces Proposed Public Offering of ADSs | COPENHAGEN, Denmark, Aug. 31, 2021 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon™ technologies to potentially create new treatments that make a meaningful differenc... |
| 25.08.2021 | Ascendis Pharma A/S Reports Second Quarter 2021 Financial Results | – Announced U.S. Food and Drug Administration Approval of SKYTROFA® (lonapegsomatropin-tcgd), the First Once-weekly Treatment for Pediatric Growth Hormone Deficiency –
– Exceeded target enrollment in Phase 3 PaTHway Trial for TransCon PTH (... |
| 25.08.2021 | Ascendis Pharma A/S Announces U.S. Food and Drug Administration Approval of SKYTROFA® (lonapegsomatropin-tcgd), the First Once-weekly Treatment for Pediatric Growth Hormone Deficiency | - SKYTROFA, the first FDA approved treatment utilizing TransCon™ technology, is a long-acting prodrug of somatropin that releases the same somatropin used in daily therapies –
- Once weekly SKYTROFA demonstrated higher annualized height vel... |
| 12.06.2021 | ASCENDIS PHARMA A/S
Ascendis Pharma A/S Announces Extension of U.S. Food and Drug Administration Review Period for TransCon™ hGH (Lonapegsomatropin) for Pediatric Growth Hormone Deficiency | COPENHAGEN, Denmark, June 11, 2021 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon technologies to create new product candidates that address unmet medical needs, tod... |
| 28.05.2021 | ASCENDIS PHARMA A/S
Ascendis Pharma A/S Invites the Public to Attend “A Story of Courage: Living with Hypoparathyroidism” in Support of World Hypopara Awareness Day on June 1, 2021 | COPENHAGEN, Denmark, May 28, 2021 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon™ technologies to create new product candidates that address unmet medical needs, tod... |
